摘要
目的对卡培他滨联合多西他赛对照多西他赛联合表柔比星治疗转移性乳腺癌的现状进行经济学评价。方法基于两方案治疗转移性乳腺癌疗效评价的Meta分析结果,以直接医疗成本进行成本计算,用Tree Age Pro 2009软件构建决策树,进行成本效果分析及敏感性分析。结果与多西他赛联合表柔比星相比,卡培他滨联合多西他赛的成本效果比大,影响因素分析及单因素敏感性分析表明,其成本效果分析的结果稳定。结论两方案的疗效相当,而成本效果分析表明,在完成相应治疗周期后,多西他赛联合表柔比星更具有经济学优势。
OBJECTIVE To evaluate the economic significance of capecitabine plus docetaxel versus epirubicin plus docetaxel for advanced or metastatic breast cancer. METHODS Based on Meta-analysis of the clinical efficacy of two regimes, selected the direct medical costs as the cost of each regime, established a decision tree with Tree Age Pro 2009 software, and made a cost-effectiveness analysis and sensitivity analysis. RESULTS After treatment cycles, the cost-effectiveness ratio of capecitabine plus docetaxel was higher than that of docetaxel and epirubicin. The stability of results was affected by fewer variables according to sensitivity analysis. CONCLUSION Two regimes are of similar efficacy, while cost of epirubicin plus docetaxel regime is of economic advantage.
出处
《中国现代应用药学》
CAS
CSCD
2015年第4期493-497,共5页
Chinese Journal of Modern Applied Pharmacy
基金
"十二五"国家科技支撑计划课题(2013BAI06B04)
